Similarly, in gefitinib-resistant EGFR-mutant NSCLC cell lines (HCC827GR and PC9GR), decreased expression of miR-483-3p, which is caused by hypermethylation of its promoter, upregulates αvβ3 integrin expression and the subsequent activation of the FAK/ERK pathway, thereby promoting EMT and subsequent acquired gefitinib resistance [85]. Here, EGFR is linked to non-small cell lung carcinoma.